Figure 5.
TME-responsive NPs for PDT-driven cancer immunotherapy. (A) Schematic illustration of pH-responsive NPs for high efficient PDT, induction of ICD, and inhibition of IDO pathway. Reproduced with permission 36. Copyright 2020, American Chemical Society. (B) Schematic illustration of GSH-responsive NPs for PDT-induced immune response and improved tumor-targeting cancer immunotherapy. Reproduced with permission 82. Copyright 2019, American Chemical Society. (C) Schematic illustration of ROS-responsive NPs for cascaded amplification of PDT and strong systemic antitumor immune responses. Reproduced with permission 83. Copyright 2020, Elsevier Ltd. (D) Schematic illustration of Hypoxia-responsive NPs for hypoxia-triggered conversion, PDT-induced immune response and vaccine immunotherapy. Reproduced with permission 84. Copyright 2019, American Chemical Society.